New Screening and Diagnostic Cut-off Points of PA Patients (NCT06571084) | Clinical Trial Compass
RecruitingNot Applicable
New Screening and Diagnostic Cut-off Points of PA Patients
China770 participantsStarted 2024-01-04
Plain-language summary
This study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoassay.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18-75y;
* persistent hypertension (BP \>150/100 mm Hg), or drug-resistant hypertension;
* newly diagnosed hypertension;
* hypertension and spontaneous or diuretic-induced hypokalemia;
* hypertension with adrenal incidentaloma;
* hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (\<40 years);
* status as a hypertensive first-degree relative of patients with PA;
* patients with hypertension and obstructive sleep apnea.
Exclusion Criteria:
* age \<18; BMI ≤ 18.0kg/m2 or ≥ 35.0 kg/m2;
* a diagnosis of secondary hypertension other than PA;
* chronic cardiac dysfunction (NYHA III-IV);
* medium and several kidney dysfunction (Ccr\<30ml/min);
* liver cirrhosis;
* terminal malignant tumor;
* recent use of steroids or oral contraceptives;
* pregnancy or lactation.
What they're measuring
1
Preliminary confirmation positive for primary aldosteronism
Timeframe: 1 month
Trial details
NCT IDNCT06571084
SponsorChina National Center for Cardiovascular Diseases